Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; RheoSwitch inducible gene switch; Cell Systems Informatics; AttSite Recombinases; Protein Engineering; antibody discovery; LEAP processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor altering chemical or antioxidant additives; and commercial aquaculture products. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Intrexon (XON) Stock Plunges Amid Proposal to Limit Florida Keys Mosquitoes Population NEW YORK (TheStreet) -- Intrexon (XON - Get Report) stock is plummeting by 13.93% to $31.70 in mid-morning trading on Thursday, as the company's Oxitec unit has proposed releasing genetically-engineered mosquitoes to reduce the Aedes aegypti strain, which transmits the Zika virus, and other mosquito-borne diseases.
Good shopping - Company responds to false article http://investors.dna.com/2016-04-22-Intrexon-Provides-Update-on-Recent-Stock-Trading-Activity
$XON I have said it many times but Rachel Carson would be working for Intrexon. Oxitec in a way was what she dreamed happening last Century
^^ Not holding my breath BUT would be great if it moved from here back up to same levels it did back in 2014!!
recent bounce still below august highs. About only help is recent biotech rally. Don't see much on near term horizon that will help.
might be the time to buy - insiders picked up more in $12's & still holding @ higher levels + news from couple days back >>> ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting - https://finance.yahoo.com/news/ziopharm-presents-positive-updated-results-120000676.html
